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Abstract
Lipid biosynthesis is essential for the maintenance of cellular homeostasis. The lipids produced by
cells (glycerolipids, fatty acids, phospholipids, cholesterol, spingolipids) are used as an energy
source/reserve, as building blocks for membrane biosynthesis, as precursor molecules for the
synthesis of various cellular products and as signaling molecules. Defects in lipid synthesis or
processing contribute to the development of many diseases, including obesity, insulin resistance,
type 2 diabetes, non-alcoholic fatty liver disease, and cancer. Studies published over the last few
years have shown that the target of rapamycin (TOR), a conserved serine/threonine kinase playing
key roles in regulating cell growth, controls lipid biosynthesis through various mechanisms. Here,
we review these findings and briefly discuss their potential relevance for human health and
disease.
The mammalian TOR (mTOR) protein is a serine-threonine kinase belonging to the
phosphoinositide 3-kinase (PI3K)-related kinase family that plays key roles in regulating
cell growth and metabolism. As depicted in Figure 1, mTOR nucleates at least two distinct
multi-protein complexes, mTOR complex 1 (mTORC1) and complex 2 (mTORC2)
(reviewed in [1]). mTORC1 integrates four major signals – growth factors, energy status,
oxygen, and amino acids to regulate many processes involved in the promotion of cell
growth and metabolism. mTORC2, that is activated by growth factors, regulates cell
survival, cell metabolism, and cytoskeletal organization (reviewed in [2]).
From yeast to mammals, favorable conditions such as nutrient and oxygen availability
induce cell growth by activating the TOR pathway. For many years, regulation of cell
growth by mTOR has been essentially studied in relation to protein synthesis, the best-
characterized biological output controlled by this pathway. However, it is becoming
increasingly clear that mTOR also controls cell growth by promoting the activation of other
anabolic processes leading to the synthesis of many classes of lipids (unsaturated and
saturated fatty acids, phosphatidylcholine, phosphatidylglycerol, and sphingolipids) required
for membrane biosynthesis and energy storage. Here, we review these findings and discuss
their potential relevance for the treatment of human diseases including cancer, obesity, and
non-alcoholic fatty liver disease (NAFLD).
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mTORC1 controls lipid synthesis through various effectors
SREBP-1
When total energy intake exceeds energy expenses, excess carbohydrates are converted to
fatty acids and deposited for storage as triglycerides in hepatic and adipose tissues. This
process, defined as de novo lipogenesis, is strongly driven by insulin (reviewed in [3]). The
binding of insulin to its cell surface receptor activates PI3K, promotes the production of
phosphatidylinositol (3,4,5)-triphosphate (PIP3), and increases the recruitment and the
activation of Akt at the plasma membrane (reviewed in [4]). When activated, Akt positively
regulates de novo lipogenesis by promoting glucose uptake, glycolysis, and the expression
of genes playing key roles in lipid biosynthesis (reviewed in [5]). Many lines of evidence
suggest that Akt mediates the effect of insulin on de novo lipogenesis by activating a
transcription factor named sterol regulatory element-binding protein-1 (SREBP-1) (reviewed
in [6]).
SREBPs are basic helix-loop-helix transcription factors that regulate lipid homeostasis by
controlling the expression of genes required for cholesterol, fatty acids, triglycerides, and
phospholipids synthesis. Three members of the SREBP family have been described in
mammals, SREBP-1a and -1c, which are produced by alternative splicing, and SREBP-2
that is encode by another gene. SREBP-1c and -2 are considered the most physiologically
relevant because of their high expression in lipogenic tissues (reviewed in [7]). The SREBPs
are synthesized in the endoplasmic reticulum (ER) in the form of a precursor protein. In
order to reach the nucleus and act as a transcription factor, the NH2-terminal domain of each
SREBP must be released from the ER proteolytically. SREBP-1 and -2 are cleaved and
activated in response to different signals. SREBP-2 is activated in response to cellular sterol
depletion whereas SREBP-1c, that is insensitive to sterol levels, is activated by insulin
(reviewed in [7]). Accordingly, studies using genetically engineered mouse models show
that SREBP-2 mainly controls cholesterol biosynthesis whereas SREBP-1c is involved in
insulin-mediated fatty acid synthesis (reviewed in [6]).
Insulin treatment or constitutive Akt activation rapidly induces nuclear accumulation of
SREBP-1 and the expression of lipogenic genes [8, 9]. The precise mechanism by which
insulin signaling promotes SREBP-1 cleavage has remained evasive for many years. As
shown in Figure 1 and 2, growth factors such as insulin increase Akt activity, which in turns
promotes mTORC1 activation by directly phosphorylating the tuberous sclerosis complex
1/2 (TSC1/2) and PRAS40. Porstmann et al. observed that impairing mTORC1 activity with
rapamycin blocks Akt-induced SREBP-1 nuclear localization, the expression of lipogenic
genes, and the production of various classes of lipids (unsaturated and saturated fatty acids,
phosphatidylcholine, and phosphatidylglycerol) [10]. The knock down of raptor, but not
rictor, showed similar effects, indicating that SREBP-1 activation by Akt depends on
mTORC1 but not mTORC2. This supports previous work that showed that rapamycin
reduces the expression of many SREBP-1 target genes including acetyl-CoA carboxylase
(ACC) [11], fatty acid synthase (FASN) [12], and stearoyl-CoA desaturase 1 (SCD-1) [13].
In addition to establishing a link between mTORC1 and SREBP-1, Porstmann et al. nicely
demonstrated that SREBP-1 silencing restricts mammalian cell growth and fly size,
suggesting that the PI3K/Akt/TORC1 pathway regulates cell size by promoting both protein
and lipid biosynthesis [10]. The exact mechanism by which mTORC1 promotes SREBP-1
cleavage and nuclear localization remains to be determined.
Increased de novo lipid synthesis is a hallmark of proliferating cancer cells (reviewed in
[14]). Uncontrolled growth factor signaling caused by the mutation/amplification of genes
coding for proteins involved in PI3K and Ras signaling pathways is commonly observed in
tumors and serves as a key signaling event leading to the activation of SREBP-1 and de
Laplante and Sabatini Page 2













novo lipogenesis (Figure 2). A significant body of evidences suggests that the induction of
lipid biosynthesis through the activation of SREBP-1 facilitates cancer progression by
providing the lipids required for membrane synthesis (reviewed in [14]). The observation
that mTORC1 promotes SREBP-1 activation indicates that this protein complex may play a
central role in cancer cell growth/proliferation by relaying growth factor signals to lipid
synthesis (Figure 2). These results strongly suggest that mTORC1 inhibition with
rapamycin, or with the newly characterized mTOR inhibitors [15-17], may reduce cancer
cell growth/proliferation by blocking both protein and lipid biosynthesis. Further
investigations are needed to support this hypothesis.
Non-alcoholic fatty liver disease (NAFLD), a condition produced by fat accumulation in the
liver, is the most common liver disease and can eventually lead to non-alcoholic
steatohepatitis, cirrhosis and hepatocellular carcinomas (reviewd in [18]). NAFLD is
commonly observed in obese subjects and is closely link to insulin resistance and the
metabolic syndrome. A recent study performed in obese humans pointed out an important
role of de novo lipogenesis in the excessive accumulation of hepatic triglycerides [19].
Although highly dependent on insulin for its activation, lipogenesis is paradoxically very
active in the liver of obese rodents, which are characterized by severe hepatic insulin
resistance. Interestingly, mTORC1 is also highly active in the liver of obese rodents [20]. In
addition to reducing insulin signaling by promoting insulin receptor substrate-1 (IRS-1)
phosphorylation/degradation (see Figure 1), mTORC1 hyperactivation by overfeeding may
promote lipogenesis by inducing SREBP-1c cleavage and activation. The nutrient-dependent
activation mTORC1 may explain why hepatic SREBP-1c is highly activated even in the
context of profound liver insulin resistance. Additionally, it is interesting to note that
metformin, an antidiabetic drug known to activate AMP-activated protein kinase (AMPK),
reduces hepatic lipid content by promoting fatty acid oxidation and by impairing SREBP-1c
expression and cleavage [21]. Because AMPK negatively regulates mTORC1 (Figures 1 and
2), this suggests that AMPK activators (metformin, adiponectin) may reduce fat deposition
in the liver by affecting the expression of lipogenic genes through an mTORC1/SREBP-1c-
dependent mechanism. The involvement of the mTORC1/SREBP-1c axis for the control of
lipid synthesis in the other important lipogenic tissue, i.e adipose tissue, will be discussed in
the next section.
PPAR-γ and Lipin1—Adipogenesis is the biological process leading to the formation of
mature adipocytes from adipose cell precursors. This process follows a well-orchestrated
program in which the CCAAT/enhancer binding protein-β (C/EBP-β) and C/EBP-δ triggers
the expression of C/EBP-α that in turns induces the expression of peroxisome proliferator-
activated receptor-γ (PPAR-γ), a member of the nuclear-receptor superfamilly of ligand-
activated transcription factors (reviewed in [22]). The activation of PPAR-γ leads to
profound changes in gene expression that ultimately lead to the stimulation of fatty acid
uptake, synthesis, esterification, and storage in the newly formed adipose cell.
Rapamycin strongly inhibits the adipogenic program in mouse and human pre-adipocytes in
vitro [23-29]. It was initially shown that rapamycin blocks adipogenesis by impairing the
clonal expansion of pre-adipocytes [29], an early event thought to be required for the
establishment of the normal adipogenic program in vitro (reviewed in [22]). Over the
following years, it was found that rapamycin severely reduces lipid accumulation in fat cells
even when added after clonal expansion, indicating that mTORC1 affects adipogenesis and
adipocyte maintenance through additional mechanisms [23, 24, 26, 28]. Most of the studies
linking mTOR signaling to adipogenesis were based on long-term rapamycin treatments, an
experimental condition that can also lead to mTORC2 inhibition [30]. To determine the
specific role of mTORC1 in adipogenesis and adipocyte maintenance, Polak et al. knocked
down raptor in 3T3-L1 adipocytes and observed a reduction in adipogenesis [28].
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Additionally, it was recently shown that adipose-specific deletion of rictor does not affect
adipocyte size and adipose tissue mass in vivo [31]. Although it remains to be determined if
acute knock down of rictor leads to similar effects, these observations strongly suggest that
mTORC1, but not mTORC2, plays a key role in adipogenesis in mammalian cells.
Although the exact mechanism linking mTORC1 signaling to adipogenesis and adipocyte
maintenance is unknown, observations suggest that mTORC1 may control these processes
by regulating the expression and the activation state of PPAR-γ (Figure 3). Many
independent groups have reported that mTOR inhibition with rapamycin reduces mRNA and
protein levels of PPAR-γ and C/EBP-α and the expression of numerous lipogenic genes in
vitro [23, 24, 26]. Accordingly, constitutive activation of mTORC1 through TSC2 deletion
increases PPAR-γ and C/EBP-α expression and promotes adipogenesis [32]. Some
evidences indicate that 4E-BP1 and 2, which are negative regulators of translation that are
inhibited by mTORC1, are important for the regulation of PPAR-γ and C/EBPs by
mTORC1 [27, 33]. Disruption of 4E-BP1/2 promotes the expression of PPAR-γ, C/EBP-α,
and C/EBP-δ and increases adipogenesis/lipid synthesis in mouse embryonic fibroblasts
[33]. Although the activation of S6K1, and probably other mTORC1 substrates, is induced
by the deletion of 4E-BP1/2 [33], these results suggest that mTORC1 controls adipogenesis/
lipogenesis by inducing the translation of mRNA coding for key components of the
adipogenic program, namely PPAR-γ and C/EBP-α. Additionally, the observation that
S6K1 deficient mice have a reduced adipose tissue mass and are protected against diet-
induced obesity indicates that mTORC1 may also control adipogenesis/lipogenesis through
this effector [34]. The molecular mechanism by which S6K1 may control lipid metabolism
is unknown.
It is interesting to note that mTORC1 may also regulate adipogenesis through additional and
complementary mechanisms. As discussed in the previous section, mTORC1 promotes lipid
synthesis by increasing SREBP-1 cleavage and activation [10]. SREBP-1 activation triggers
the production of endogenous ligands for PPAR-γ and this promotes the transactivation
activity of this nuclear receptor [35]. Interestingly, Kim et al. observed that the synthetic
PPAR-γ ligand troglitazone can overcome the inhibitory effect of rapamycin on
adipogenesis, suggesting that mTORC1 inhibition may block adipogenesis by reducing the
production of endogenous PPAR-γ ligands [24]. However, it is possible that troglitazone, as
an unnatural ligand, may override the normal requirements for PPAR-γ activation and thus
counters rapamycin inhibition unspecifically. The fact that conditioned media obtained from
normally differentiated adipocytes cannot correct the adipogenic defect of adipocytes treated
with rapamycin indicates that this possibility may be true [24]. Additional work is needed to
clarify this point.
Lipin1 is a phosphatidic acid phosphatase that promotes triglyceride synthesis by converting
phosphatidic acid to diacylglycerol. A null mutation in the lipin1 gene leads to
lipodystrophy whereas lipin1 overexpression causes obesity (reviewed in [36]). In addition
to directly promoting triglyceride synthesis through its phosphatidic acid phosphatase
activity, lipin1 acts as a transcriptional coactivator for many transcription factors including
PPAR-γ. Lipin1 physically interacts with PPAR-γ to induce the expression of many genes
playing key roles in adipogenesis [37]. Accordingly, studies with lipin1 null embryonic
fibroblasts revealed that lipin1 is required for the expression of key adipogenic markers,
such as PPAR-γ and C/EBP-α, and for the attainment of mature adipocyte functions,
including lipogenesis and lipid accumulation [38]. In consequence, lipin1 is though to affect
adipogenesis and adipocyte maintenance by serving as a direct promoter of triglyceride
synthesis and as an amplifier of the transcriptional activity of PPAR-γ. Lipin1 activity is
regulated through many mechanisms, including by phosphorylation. In adipocytes, lipin1 is
phosphorylated in response to insulin and amino acids in a rapamycin-sensitive fashion, thus
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suggesting that mTOR signaling may directly regulate adipogenesis/lipogenesis through the
control of lipin1 activity [39]. More work is need to characterize the biological link between
mTOR and lipin1 since the exact consequences of lipin1 phosphorylation on lipid synthesis
and gene expression have not been characterized so far.
As described throughout this section, the link between mTORC1 and PPAR-γ in the control
of adipogenesis and adipocyte maintenance has been well established in vitro. In order to
determine the role of mTORC1 in adipocytes in vivo, Polak et al. ablated mTORC1
functions in adipose tissue by crossing raptor floxed mice with mice expressing a cre-
recombinase under the control of the fatty acid binding protein-4 (FABP4)/ap2 promoter
[28]. Because this promoter is expressed after the critical steps required for the induction of
adipogenesis, this study mainly focused on the role of mTORC1 in adipocyte maintenance.
In line with the in vitro studies, raptor deletion in fat results in lean mice with a reduction in
adipocyte size and number. Unexpectedly, the expression of many genes involved in lipid
production and storage, including PPAR-γ and C/EBP-α, is not reduced in adipose tissue of
these animals. Polak et al. observed that mTORC1 inactivation reduces fat accumulation in
adipose tissue by promoting energy expenditure through an induction of uncoupled
respiration. Interestingly, similar increase in energy expenditure is observed in many animal
models deficient for protein playing key roles in lipogenesis [40-42]. This raises the
possibility that the reduction in fat mass and the induction of energy expenditure in adipose-
specific raptor null animals could be linked to a defect in lipogenesis, defect that is likely
independent of PPAR-γ-induced lipogenic gene expression. The potential implication of
lipin1 or SREBP-1 in this effect has to be considered.
Obesity, defined as an excess amount of body fat relative to lean body mass, is a major
health concern in the United States and an increasing problem in the developing world.
Recent advances regarding the biology of adipose tissue have demonstrated that the white
adipose tissue plays a central role in the control of energy balance and acts as a powerful
endocrine organ that mediates numerous physiological and pathological processes (reviewed
in [43]). It was observed that mTORC1 is highly active in adipose tissue of obese rodents
[34]. The existence of a link between mTORC1 activation and adipogenesis/lipogenesis
suggests that mTORC1 may play a significant role in the accumulation of fat when energy
intake exceeds energy expenses. Understanding the role of mTORC1 signaling in the
development and the maintenance of adipose tissue and in the control of its endocrine
function may promote the development of new pharmacologic tools to treat metabolic
diseases associated with obesity such as insulin resistance, type 2 diabetes and coronary-
vascular diseases.
Possible implication of mTORC2 in lipid biosynthesis – lessons from lower
organisms
Two recent reports indicate that impairment of TORC2 function affects fat accumulation in
C.elegans [44, 45]. Despite developmental delay and reduced body size, rictor null worms
show increased body fat accumulation, thus suggesting that TORC2 functions as a negative
regulator of lipid deposition in this model. Jones et al. found that the induction of lipid
storage in rictor null C.elegans depends on the TORC2 substrate SGK1 but not Akt, as only
SGK1 loss can mimic the metabolic phenotype associated with rictor deletion [44]. The
precise mechanism linking the TORC2/SGK1 axis to lipid metabolism was not described in
this study. In the other report, Soukas et al. observed that the high-fat phenotype associated
with rictor loss is associated with a reduction in oxygen consumption and is dependent on
SGK1, but also Akt1 and Akt2 [45]. Soukas et al. also show that the site of action of rictor
in the regulation of fat mass is the intestine, which is the key site for fat storage in C.elegans.
Although the conclusions drawn in these reports do not perfectly match, these studies
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demonstrate that TORC2 plays a significant role in regulating fat accumulation in C.elegans
and that SGK1 is required in this process. An interesting question arising from these
observations is whether or not a similar link between mTORC2 and lipid synthesis exists in
mammalian cells. The fact that adipose-specific rictor null mice [31] and whole-body SGKs
deficient mice models (reviewed in [46]) do not show any defect in lipid metabolism
suggests that mTORC2 may have a more subtle role to play in the control of lipid
metabolism in mammals. Whether or not this is a consequence of the higher genetic
redundancy of mammalian systems remains to be determined.
Although the implication of mTORC2 in the control of lipogenesis/adipogenesis appears to
be limited in mammals, recent observations in yeast suggest that this complex may regulate
other facets of lipid metabolism. Aranova et al. recently showed that the synthesis of minor
and major ceramides species is impaired in yeast cells deficient in TORC2 activity [47]. In
the same report, it was observed that TORC2 controls de novo sphingolipid synthesis by
regulating the activity of ceramide synthase through a mechanism dependent on Ypk2, the
yeast homologue of SGK1. Although the exact mechanism linking Ypk2 to ceramide
synthase has not been characterized, these results indicate that TORC2 plays a role in
transmitting growth signals to sphingolipid synthesis in yeast. Because the early steps in de
novo sphingolipid synthesis are well conserved throughout evolution (reviewed in [48]), it is
reasonable to believe that mTORC2 could control this pathway in mammals. Sphingolipids,
which include sphigosine and ceramides, have been implicated in a variety of physiological
functions including differentiation, cell migration and adhesion, cell growth arrest,
senescence and apoptosis. These lipids are believed to play important roles in many
pathological settings including cancer, heart disease, diabetes, microbial infection,
neurological disorders and immune dysfunctions. The possible implication of mTORC2 in
the regulation of ceramide levels indicates that mTORC2 may play important and yet
undefined roles in these diseases and may also represent an interesting target for the
development of new therapeutic avenues. Additional studies are required to determine if
mTORC2 plays a significant role in controlling de novo shingolipid synthesis in mammalian
cells.
Concluding remarks
Lipid biosynthesis is essential for the maintenance of cellular homeostasis and defects in
lipid synthesis or processing contribute to the development of many diseases, including
obesity, insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease, and cancer.
Over the last decade, many groups have shown that mTOR signaling regulates lipid
synthesis through various effectors, suggesting that this pathway could be targeted for the
development of new therapeutic tools for the treatment of many diseases. Despite
outstanding advances, our understanding of the mechanisms by which mTOR signaling
affect lipid synthesis in mammals is incomplete and important questions remain to be
answered. For example, how does mTORC1 promote SREBP-1 cleavage and nuclear
localization? What is the exact mechanism by which mTORC1 regulates the activity of
PPAR-γ? How does mTORC1 control lipid synthesis in adipose tissue in vivo? What is the
biological function associated with lipin1 phosphorylation by mTOR? What is the exact role
of mTORC2 in the regulation of lipogenesis? Does mTORC2 regulate sphingolipid
synthesis in mammals? Finding answers to these questions will improve our understanding
of cell biology and may help to improve the way we treat many diseases.
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Figure 1. Overview of the mTOR signaling pathway
The mTOR kinase nucleates two characterized protein complexes termed mTORC1 and
mTORC2. mTORC1 is composed of 5 subunits : (i) the mTOR catalytic subunit, (ii) Raptor,
(iii) mLST8, (iv) PRAS40, and (v) Deptor. The mTORC2 complex contains 6 proteins (i)
mTOR, (ii) Rictor, (iii) mSin1, (iv) Protor-1, (v) mLST8, and (vi) Deptor. mTORC1 is
sensitive to nutrients and is inhibited by FKBP12-rapamycin. One of the most important
sensors involved in the regulation of mTORC1 activity is TSC, which is a heterodimer
composed of TSC1 and TSC2. TSC1/2 functions as a GTPase GAP for the small, Ras-
related GTPase, Rheb. The active, GTP-bound form of Rheb directly interacts with
mTORC1 to stimulate its activity. As a Rheb-specific GAP, TSC1/2 negatively regulates
mTORC1 signaling by converting Rheb into its inactive GDP-bound state. Stimulation of
cells with growth factors activates Akt, Erk, and Rsk, which inactivates TSC and promotes
Rheb activation. Akt activation also promotes mTORC1 activity by phosphorylating
PRAS40, a negative regulator of mTORC1. At the opposite, induction of Redd1 and AMPK
by hypoxia and energy deficit activates TSC1/2 and turn down mTORC1 signaling. The
activation of mTORC1 by amino acids is regulated by the Rag GTPase and is independent
of TSC1/2. Activation of mTORC1 by growth factors or amino acids promotes protein
synthesis via the phosphorylation of S6K1 and 4EBPs. High activation of S6K1 by
mTORC1 induces a feedback inhibition loop in which S6K1 reduces growth factor signaling
by promoting the phosphorylation and the degradation of IRS-1. mTORC2 is activated by
growth factors and regulates many AGC kinases (Akt, SGK1, PKC-α) playing key roles in
controlling cell survival, metabolism and cytoskeletal organization. This complex is
insensitive to FKBP12-rapamycin but is inhibited by the newly characterized mTOR
inhibitor Torin1. Akt, protein kinase B; AMPK, AMP-activated protein kinase; Deptor, DEP
domain containing protein associated with mTOR; Erk, extracellular signal-regulated
kinase; FKBP12, intracellular receptor for rapamycin; GAP, GTPase activating protein;
IRS-1, insulin receptor substrate-1; mLST8, mammalian lethal with Sec13 protein 8;
mSIN1, mammalian stress-activated protein kinase interacting protein PKC-α, protein
kinase C-α; PRAS40, proline-rich Akt substrate 40kDa; Protor1, protein observed with
rictor-1; Raptor, regulatory-associated protein of mTOR; Redd1, transcriptional regulation
of DNA damage response-1; Rheb, Ras homolog enriched in brain; Rictor, rapamycin
insensitive companion of mTOR; Rsk, ribosomal S6 kinase; SGK1, serum- and
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glucocorticoid-induced protein kinase 1; S6K1, p70 ribosomal S6 kinase 1; TSC1/2,
tuberous sclerosis complex 1 and 2; 4EBPs, eukaryotic initiation factor 4E-binding proteins.
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Figure 2. mTORC1 promotes de novo lipogenesis through the activation of SREBP-1
The activation of mTORC1 in response to growth factors induces many anabolic processes
that favors cell growth and proliferation. In addition of promoting protein synthesis through
the phosphorylation of S6K1 and 4EBPs, mTORC1 controls de novo lipid synthesis by
regulating the activation state of SREBP-1. In details, growth factors activate Akt, Erk and
Rsk, which induce TSC1/2 phosphorylation and lead to mTORC1 activation. Akt also
directly promotes mTORC1 action through the phosphorylation of PRAS40. When
activated, mTORC1 favors the cleavage of SREBP-1 by a mechanism that remains to be
established. The cleaved form of SREBP-1 then translocates to the nucleus where it induces
the expression of many lipogenic genes including ACC, ACLY, FASN, GPAT, GK and
SCD1. Mutations in tumor suppressors or oncogenes that lead to the overactivation of Ras
and insulin signaling pathways are commonly observed in cancer and are thought to promote
cell growth and proliferation by inducing many anabolic processes including lipid
biosynthesis. The induction of lipogenesis through the activation of SREBP-1 promotes
cancer progression by providing the lipids required for membrane synthesis. The fact that
mTORC1 promotes SREBP-1 activation indicates that this protein complex may play a
central role in cancer cell growth/proliferation by relaying growth factor signals to lipid
synthesis. ACC, acetyl-CoA carbolxylase; ACLY, acyl-CoA lyase; FASN, fatty acid
synthase; ER, endoplasmic reticulum; SCD-1, stearoyl-CoA desaturase-1; GPAT,
glycerol-3-phosphate acyltransferase; GK, glucokinase; GLUT4, glucose transporter 4;
Grb2, growth factor receptor bound protein 2; NF-1, neurofibromatosis type 1; PDK1,
phosphoinositide-dependent kinase 1; PTEN, phosphatase and tensin homologue deleted on
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chromosome 10; SOS, son of sevenless; nSREBP-1, nuclear form of sterol regulatory
element-binding protein-1; TCA cycle, tricarboxilic acid cycle.
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Figure 3. mTORC1 promotes adipogenesis and adipocyte maintenance through various
mechanisms
Many evidences indicates that mTORC1 controls adipogenesis by activating PPAR-γ, a
nuclear receptor controlling the expression of numerous genes involved in fatty acid uptake,
synthesis, esterification, and storage. Many mechanisms are though to be involved in the
regulation of PPAR-γ by mTORC1. Activation of mTORC1 induces the phosphorylation of
4E-BPs, which in turn releases eIF4E and increases the translation of C/EBP-α and -δ,
which are key components required for the establishment of the adipogenic cascade. C/EBP-
δ is known to drive the expression of C/EBP-α and PPAR-γ and to trigger the activation of
a feed-forward loop in which these two transcription factors reciprocally induce their
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expression. When sufficient levels of PPAR-γ proteins are produced, this transcription
factor promotes adipogenesis and lipid synthesis by inducing the expression of many
lipogenic genes. SREBP-1 cleavage by mTORC1 may also contribute to the induction of
adipognesis by directly favoring triglyceride synthesis and by promoting the production of
endogenous ligands for PPAR-γ. More work is required to determine if SREBP-1-
dependent production of PPAR-γ ligands plays a significant role in the activation of PPAR-
γ by mTORC1. Lipin1, a phosphatidic acid phosphatase, was shown to play key role in
adipogenesis by promoting triglyceride synthesis and by serving as a coactivator for PPAR-
γ. Lipin1 is phosphorylated in response to insulin and amino acids in a rapamycin-sensitive
fashion. Because rapamycin can inhibit mTORC2 activity in some cell types, it is unclear if
lipin1 is a direct substrate of mTORC1 or mTORC2. The biological meaning of mTOR-
mediated lipin1 phosphorylation remains to be characterized.
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